ARCH Venture Partners X, LLC - Jan 30, 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
10%+ Owner
Signature
/s/ ARCH Venture Fund X, L.P., By: ARCH Venture Partners X, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact
Stock symbol
MAZE
Transactions as of
Jan 30, 2025
Transactions value $
$0
Form type
3
Date filed
1/30/2025, 04:42 PM
Previous filing
Feb 20, 2024
Next filing
Aug 1, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MAZE Series A Preferred Stock Jan 30, 2025 Common Stock 10M ARCH Venture Fund X, L.P. F1, F2, F3
holding MAZE Series A Preferred Stock Jan 30, 2025 Common Stock 10M ARCH Venture Fund X Overage, L.P. F1, F3, F4
holding MAZE Series B Preferred Stock Jan 30, 2025 Common Stock 5.45M ARCH Venture Fund X, L.P. F2, F3, F5
holding MAZE Series B Preferred Stock Jan 30, 2025 Common Stock 7.27M ARCH Venture Fund X Overage, L.P. F3, F4, F5
holding MAZE Series D-1 Preferred Stock Jan 30, 2025 Common Stock 2.43M ARCH Venture Fund X, L.P. F2, F3, F6
holding MAZE Series D-1 Preferred Stock Jan 30, 2025 Common Stock 2.43M ARCH Venture Fund X Overage, L.P. F3, F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for- 0.1037236801. The securities have no expiration date.
F2 Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
F3 ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
F4 Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
F5 Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.
F6 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series D-1 Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.